Abstract
Red blood cell (RBC) encapsulated L-asparaginase is a novel therapeutic for the treatment of asparagine auxotrophic malignancies. The enzyme-loaded red blood cells function as bioreactors to deplete bloodstream substrate. This delivery system provides improved pharmacodynamics with protection from circulating proteolytic enzymes and avoidance of early liver or renal clearance. The “drug” is manufactured with ABO and Rh compatible donor blood when a prescription is received. Because of the industrial scale manufacturing, the “drug” is transfused the day of receipt at the clinical site. Preliminary clinical studies show utility in childhood and adult acute lymphoblastic leukemia. Based on previous studies of applications in different diseases and assessment of different biomarkers, we propose this agent offers a safe and potentially effective treatment for a subset of chemotherapy refractory acute myeloid leukemia patients. The history, chemistry, biology, pharmacology, and relevant clinical experiences with L-asparaginase as well as the properties and proposed protocols with the red cell-encapsulated enzyme are reviewed.
Keywords: Red blood cell encapsulation, L-asparaginase and AML, Red blood cell (RBC), novel therapeutic, bloodstream, pharmacodynamics, proteolytic enzyme, leukemia, chemotherapy, pharmacology, encapsulated enzyme
Protein & Peptide Letters
Title:Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia
Volume: 20 Issue: 4
Author(s): Vaidehi Agrawal, Jung Hee Woo, Gautham Borthakur, Hagop Kantarjian and Arthur E. Frankel
Affiliation:
Keywords: Red blood cell encapsulation, L-asparaginase and AML, Red blood cell (RBC), novel therapeutic, bloodstream, pharmacodynamics, proteolytic enzyme, leukemia, chemotherapy, pharmacology, encapsulated enzyme
Abstract: Red blood cell (RBC) encapsulated L-asparaginase is a novel therapeutic for the treatment of asparagine auxotrophic malignancies. The enzyme-loaded red blood cells function as bioreactors to deplete bloodstream substrate. This delivery system provides improved pharmacodynamics with protection from circulating proteolytic enzymes and avoidance of early liver or renal clearance. The “drug” is manufactured with ABO and Rh compatible donor blood when a prescription is received. Because of the industrial scale manufacturing, the “drug” is transfused the day of receipt at the clinical site. Preliminary clinical studies show utility in childhood and adult acute lymphoblastic leukemia. Based on previous studies of applications in different diseases and assessment of different biomarkers, we propose this agent offers a safe and potentially effective treatment for a subset of chemotherapy refractory acute myeloid leukemia patients. The history, chemistry, biology, pharmacology, and relevant clinical experiences with L-asparaginase as well as the properties and proposed protocols with the red cell-encapsulated enzyme are reviewed.
Export Options
About this article
Cite this article as:
Agrawal Vaidehi, Hee Woo Jung, Borthakur Gautham, Kantarjian Hagop and E. Frankel Arthur, Red Blood Cell-Encapsulated L-Asparaginase: Potential Therapy of Patients with Asparagine Synthetase Deficient Acute Myeloid Leukemia, Protein & Peptide Letters 2013; 20 (4) . https://dx.doi.org/10.2174/0929866511320040003
DOI https://dx.doi.org/10.2174/0929866511320040003 |
Print ISSN 0929-8665 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5305 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Targeting Proteasomes with Naturally Occurring Compounds in Cancer Treatment
Current Cancer Drug Targets Anti-CD20 Antibody in Primary Sjogren's Syndrome Managemen
Current Pharmaceutical Biotechnology Critical Roles of EGFR Family Members in Breast Cancer and Breast Cancer Stem Cells: Targets for Therapy
Current Pharmaceutical Design Targeting Transcription Factor Binding to DNA by Competing with DNA Binders as an Approach for Controlling Gene Expression
Current Topics in Medicinal Chemistry The Significance of Transferrin Receptors in Oncology: the Development of Functional Nano-based Drug Delivery Systems
Current Drug Delivery Cancer Therapy: Targeting Mitochondria and other Sub-cellular Organelles
Current Pharmaceutical Design Eph/Ephrin Membrane Proteins: A Mammalian Expression Vector pTIg- BOS-Fc Allowing Rapid Protein Purification
Protein & Peptide Letters Germ Cell Apoptosis: Relevance to Infertility and Contraception
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) DNA-Damaging Anticancer Drugs – A Perspective for DNA Repair- Oriented Therapy
Current Medicinal Chemistry Overview of Brain Tumor Stem Cells – Implications for Treatment
Current Signal Transduction Therapy Peripheral Benzodiazepine Receptor Ligands and their Anti-Inflammatory Effects
Current Medicinal Chemistry - Anti-Inflammatory & Anti-Allergy Agents Antioxidant, Pro-Oxidant and Other Biological Activities of Sesquiterpenes
Current Topics in Medicinal Chemistry The Potential of Peroxisome Proliferator-Activated Receptor γ (PPARγ) Ligands in the Treatment of Hematological Malignancies
Mini-Reviews in Medicinal Chemistry Emerging Role of Wnt/Beta-Catenin Signalling Pathways in Cancer Progression and Role of Small Molecule Tankyrase Inhibitors in Combating Multistage Cancers
Current Cancer Therapy Reviews Ginkgo biloba Extract in Vascular Protection: Molecular Mechanisms and Clinical Applications
Current Vascular Pharmacology New Hopes in Cancer Battle - A Review of New Molecules and Treatment Strategies
Medicinal Chemistry The Role of Phospholipase D Enzyme(s) in Modulating Cell Signaling: Implications for Cancer Drug Development
Current Bioactive Compounds HDAC as a Therapeutic Target for Treatment of Endometrial Cancers
Current Pharmaceutical Design Molecules of Parasites as Immunomodulatory Drugs
Current Topics in Medicinal Chemistry Farnesyltransferase Inhibitors: A Comprehensive Review Based on Quantitative Structural Analysis
Current Medicinal Chemistry